Showing 2471-2480 of 20412 results for "".
Analyzing IL-31 and the Benefits of Blocking It
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/analyzing-il-31-and-the-benefits-of-blocking-it/48777/James Q. Del Rosso, DO, FAOCD, discusses IL-31 and its involvement with itch, impairment of skin barrier function, and increased fibrosis of the skin.Individualizing gMG Treatment: Defining Success With Each Patient
https://reachmd.com/programs/neurofrontiers/individualizing-gmg-treatment-defining-success-with-each-patient/32862/As treatment options for generalized myasthenia gravis (gMG) expand, defining success means more than just controlling symptoms—it means aligning care with each patient’s goals and lifestyle. Hear Dr. Omar Sinno, who spoke with ReachMD at the AANEM 2025 Annual Meeting in San Francisco, share insightInnovations in Bladder Monitoring for MS: Advancing Remote Evaluation Tools
https://reachmd.com/programs/neurofrontiers/innovations-in-bladder-monitoring-for-ms-advancing-remote-evaluation-tools/32803/Many patients with multiple sclerosis (MS) experience neurogenic bladder symptoms—ranging from urgency and incontinence to retention and infection risk—but these issues are often underprioritized in care. Based on recent research, remote, commercially available bladder monitoring tools can help addrReviewing RSV in Immunocompromised Adults
https://reachmd.com/programs/deep-breaths-updates-chest/reviewing-rsv-in-immunocompromised-adults/15336/How common is RSV in immunocompromised adults? Dive in.Iron Sequestration in Microbiota Biofilms in Treatment for IBD
https://reachmd.com/programs/Audioabstracts/iron-sequestration-in-microbiota-biofilms-in-treatment-for-ibd/10712/This integrative study provides deeper understanding of the interactivity between microbiota and anti-inflammatory drugs currently used to treat IBD.Behind-the-Scenes Look into Health Information Exchange
https://reachmd.com/programs/primary-care-today/behind-the-scenes-look-into-health-information-exchange/10493/An astounding electronic evolution is continuing to improve healthcare and the transfer of information. How will data transform your patients’ care?Top Non-Pharmacologic Interventions for Rheumatoid Arthritis
https://reachmd.com/programs/conference-coverage/top-non-pharmacologic-interventions-for-rheumatoid-arthritis/10303/When it comes to improving your rheumatoid arthritis patients’ symptoms, these non-pharmacologic interventions cannot be overlooked.FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
https://reachmd.com/programs/FDA-Drug-Information-Updates/fda-review-adding-labas-ics-treatment-does-not-significantly-increase-serious-asthma-outcomes-risk/9950/The FDA found no significant increase in risk of serious asthma outcomes combining long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS)The Angry Smile: Exploring the Psychological Impacts of Passive-Aggressive Behavior
https://reachmd.com/programs/primary-care-today/angry-smile-exploring-psychological-impacts-passive-aggressive-behavior/9712/Author Signe Whitson offers real-world examples and empowering, practical strategies for individuals confronted with passive aggressiveness.Therapeutic Mechanism of Action (MOAs) in MS: Targeting T- and B-cells to Reset the Immune System
https://reachmd.com/programs/global-neurology-academy/therapeutic-mechanism-action-moas-ms-targeting-t-and-b-cells-reset-immune-system/9533/This lecture was given live at Regional Medical Update Dinner on Current and Future Treatments educational program, which was held in select European cities. This highly-interactive live educational meeting will provide attendees with the most recent information concerning new and emerging treatment